Effects of polyunsaturated free fatty acids and esterified linoleoyl derivatives on oxygen consumption and C6-aldehyde formation with soybean seed homogenates

1991 ◽  
Vol 39 (8) ◽  
pp. 1357-1364 ◽  
Author(s):  
Hong Zhuang ◽  
David F. Hildebrand ◽  
Roger A. Andersen ◽  
Thomas R. Hamilton-Kemp
1976 ◽  
Vol 37 (1) ◽  
pp. 167 ◽  
Author(s):  
William J. Rogers ◽  
Richard O. Russell ◽  
Roger E. Moraski ◽  
Huey G. McDaniel ◽  
Charles E. Rackley

1979 ◽  
Vol 57 (7) ◽  
pp. 725-730 ◽  
Author(s):  
Louise Lafrance ◽  
Danièle Routhier ◽  
Bernard Têtu ◽  
Christian Têtu

A 3-h noradrenaline (NA) infusion (1.5 μg kg−1 min−1) produced a sustained enhanced oxygen consumption (O2 cons.) in cold-adapted rats. Plama free fatty acid (FFA) levels were elevated by NA in control and in cold-adapted rats, but to a lesser extent in cold-adapted rats; the increase was maintained at a plateau in both groups during the entire period of NA infusion. A 1-h nicotinic acid (Nic A) infusion (1.5 mg kg−1 min−1) added to the NA infusion inhibited the calorigenic response to NA in cold-adapted rats and reduced the elevated plasma FFA concentration in control and in cold-adapted rats to values below basal levels. However, when the Nic A infusion was stopped, the O2 cons, was increased again in cold-adapted rats by the uninterrupted NA infusion, without the simultaneous increase of the plasma FFA concentration; the plasma FFA concentration was maintained in cold-adapted rats below basal values and merely brought back to basal levels in control rats. From these results, it is suggested that plasma FFA are not an essential substrate to the calorigenic response to NA observed in cold-adapted rats, as 85% of the response can occur when the plasma FFA concentration is very low.


2000 ◽  
Vol 89 (2) ◽  
pp. 549-556 ◽  
Author(s):  
Michael A. Morrison ◽  
Lawrence L. Spriet ◽  
David J. Dyck

The purposes of the present studies were to test the hypotheses that lower dosages of oral pyruvate ingestion would increase blood pyruvate concentration and that the ingestion of a commonly recommended dosage of pyruvate (7 g) for 7 days would enhance performance during intense aerobic exercise in well-trained individuals. Nine recreationally active subjects (8 women, 1 man) consumed 7, 15, and 25 g of pyruvate and were monitored for a 4-h period to determine whether blood metabolites were altered. Pyruvate consumption failed to significantly elevate blood pyruvate, and it had no effect on indexes of carbohydrate (blood glucose, lactate) or lipid metabolism (blood glycerol, plasma free fatty acids). As a follow-up, we administered 7 g/day of either placebo or pyruvate, for a 1-wk period to seven, well-trained male cyclists (maximal oxygen consumption, 62.3 ± 3.0 ml · kg−1 · min−1) in a randomized, double-blind, crossover trial. Subjects cycled at 74–80% of their maximal oxygen consumption until exhaustion. There was no difference in performance times between the two trials (placebo, 91 ± 9 min; pyruvate, 88 ± 8 min). Measured blood parameters (insulin, peptide C, glucose, lactate, glycerol, free fatty acids) were also unaffected. Our results indicate that oral pyruvate supplementation does not increase blood pyruvate content and does not enhance performance during intense exercise in well-trained cyclists.


Sign in / Sign up

Export Citation Format

Share Document